Ipamorelin 5 mg

DRAGON PHARMA IPAMORELIN

Dragon Pharma Ipamorelin 5 mg represents the gold standard in selective growth hormone secretagogue therapy for athletes, bodybuilders, and fitness enthusiasts in the United States. This fifth-generation synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) stands apart from other growth hormone releasing peptides (GHRPs) through its remarkable selectivity—stimulating natural growth hormone release without triggering cortisol, prolactin, or aldosterone secretion. Each 2 mL vial contains 5 mg of pharmaceutical-grade lyophilized Ipamorelin powder, manufactured under strict pharmaceutical standards to ensure maximum purity, stability, and biological activity. Third-party laboratory testing confirms exceptional potency at 5.60 mg per vial, demonstrating Dragon Pharma's commitment to quality and accuracy that exceeds labeled claims.

DRUG COMPOSITION

Each vial contains 5 mg of Ipamorelin acetate as a white to off-white lyophilized powder. The specific amino acid sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2 (where Aib = aminoisobutyric acid, D-2-Nal = D-2-naphthylalanine). This synthetic pentapeptide is a growth hormone secretagogue (GHS) that selectively binds to the ghrelin receptor (GHS-R1a). The product contains no additional excipients, fillers, or preservatives, ensuring maximum purity and minimizing potential allergic reactions. The lyophilization process removes water through freeze-drying, resulting in a stable powder that maintains potency throughout its 24-month shelf life when stored properly. This pharmaceutical-grade formulation ensures rapid reconstitution and complete bioavailability when prepared with bacteriostatic water.

PHARMACEUTICAL FORM

Sterile lyophilized powder for injection in a 2 mL glass vial sealed with a gray rubber stopper and aluminum cap. The lyophilized form offers superior stability compared to liquid preparations, with extended shelf life and reduced risk of microbial contamination. The powder reconstitutes quickly with bacteriostatic water or sterile saline, forming a clear, colorless solution suitable for subcutaneous injection. Each vial is individually packaged with tamper-evident seals and includes batch-specific quality control documentation. The absence of preservatives makes this formulation ideal for individuals with sensitivities to common pharmaceutical additives like benzyl alcohol. The 2 mL volume allows for flexible reconstitution concentrations based on individual dosing preferences.

PHARMACEUTICAL GROUP AND ATC CODE

Ipamorelin belongs to the therapeutic category of anterior pituitary lobe hormones and analogs (ATC code: H01AC). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under hypothalamic and pituitary hormone analogues. Specifically, it's classified as a growth hormone secretagogue (GHS). In sports medicine and performance enhancement, it's categorized as a selective growth hormone releasing peptide with lipolytic, regenerative, and anti-aging properties. Unlike earlier GHRPs, Ipamorelin exhibits remarkable receptor specificity for GHS-R1a without cross-reactivity with other pituitary hormone pathways.

PHARMACOLOGICAL PROPERTIES

Ipamorelin exerts its primary effects through selective agonism of the growth hormone secretagogue receptor (GHS-R1a), triggering intracellular signaling cascades that result in growth hormone (GH) release from anterior pituitary somatotrophs. Unlike other GHRPs like GHRP-6 or Hexarelin, Ipamorelin demonstrates exceptional selectivity—it doesn't stimulate cortisol, prolactin, or aldosterone secretion. According to research published in the Journal of Endocrinology, Ipamorelin increases GH levels in a dose-dependent manner while maintaining normal pulsatile secretion patterns and feedback regulation. The peptide enhances lipolysis, improves nitrogen retention, stimulates collagen synthesis, supports immune function, and promotes slow-wave sleep without causing GH receptor desensitization or disrupting natural circadian rhythms.

THERAPEUTICAL INDICATIONS

Dragon Pharma Ipamorelin 5 mg is indicated for: stimulation of natural growth hormone production in age-related decline (somatopause), reduction of adipose tissue particularly visceral fat, acceleration of recovery from intense training and injury, enhancement of sleep quality and duration, improvement of skin quality and collagen synthesis for anti-aging benefits, support of joint and connective tissue health, optimization of body composition during cutting phases, improvement of exercise performance and endurance, and general metabolic enhancement. It's particularly valuable for bodybuilders during contest preparation, athletes seeking performance enhancement without exogenous GH, individuals over 30 experiencing natural GH decline, and those seeking sustainable anti-aging interventions.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 5 mg vial with 1-2 mL of bacteriostatic water to achieve concentrations of 2.5-5 mg/mL. Standard dosing protocols range from 100-300 mcg (0.1-0.3 mg) administered subcutaneously once to three times daily. For anti-aging and general wellness: 100-200 mcg daily. For fat loss and body recomposition: 200-300 mcg daily, typically divided into two doses (morning and evening). For maximum recovery enhancement: 300 mcg daily, often as a single bedtime dose. Administration should be subcutaneous in abdominal, thigh, or triceps adipose tissue, rotating injection sites to prevent lipohypertrophy. Optimal timing is 30-60 minutes before bedtime to leverage natural nocturnal GH pulses. Treatment cycles typically last 12-24 weeks with 4-8 week breaks between cycles.

CYCLE/STACKING

Ipamorelin stacks synergistically with various compounds to enhance specific outcomes. Combine with CJC-1295 No DAC for amplified GH pulses through complementary receptor pathways. Stack with Sermorelin 5 mg for enhanced GHRH activity alongside GHS action. For accelerated fat loss during cutting, add T4 to increase metabolic rate synergistically. During muscle-building phases, combine with Masteron 100 for quality muscle accrual with enhanced hardness. For comprehensive metabolic and cognitive benefits, include NAD+ to support cellular energy production alongside GH optimization.

POST CYCLE THERAPY

Ipamorelin serves as an excellent adjunct during post-cycle therapy by supporting recovery processes that may be compromised after anabolic cycles. Growth hormone enhances protein synthesis, improves connective tissue integrity, supports metabolic function, and promotes quality sleep—all valuable during the hormonal transition of PCT. Administer 100-200 mcg daily during PCT to help maintain lean mass while reducing body fat that often accumulates during recovery. The improved sleep quality from GH optimization helps combat PCT-related fatigue and supports overall recovery. Continue for 4-8 weeks post-cycle to maximize benefits. Unlike exogenous testosterone or other anabolics, Ipamorelin doesn't suppress the HPTA axis and may actually support natural hormone production through improved metabolic health.

SIDE EFFECTS

Ipamorelin is exceptionally well-tolerated with minimal side effects due to its selective action. Some users report mild injection site reactions (redness, itching, or discomfort) that typically resolve within 24 hours. Unlike other GHRPs, Ipamorelin doesn't stimulate hunger—a significant advantage for those concerned about appetite increases. Rare side effects include temporary joint stiffness or mild fluid retention during initial adaptation period, usually resolving within 1-2 weeks. No cases of cortisol elevation, prolactin increases, organ toxicity, hormonal suppression, or serious adverse events have been reported at therapeutic doses in clinical studies. The exceptional selectivity profile makes Ipamorelin suitable for long-term use with minimal side effect concerns.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to Ipamorelin or any component of the formulation. Not recommended for individuals with active cancer or recent malignancy history, as GH may stimulate cell proliferation. Use with caution in individuals with diabetes or glucose intolerance, as GH affects insulin sensitivity—monitor blood glucose closely. Those with acromegaly or gigantism should avoid use. Not for use during pregnancy or lactation due to insufficient safety data. Individuals with severe renal or hepatic impairment should consult a healthcare provider before use. Not recommended for pediatric use or individuals under 21 years of age. Those with untreated hypothyroidism may require optimization before Ipamorelin use.

OVERDOSE

Acute overdose is unlikely due to the peptide nature of the compound and its rapid metabolism. Symptoms of excessive dosing may include pronounced joint stiffness, fluid retention, carpal tunnel-like symptoms, or temporary glucose elevation. In cases of significant overdose, discontinue use and allow the peptide to clear from the system (typically 4-6 hours). Supportive care includes monitoring glucose levels in diabetic individuals and ensuring adequate hydration. No specific antidotes exist, but symptoms are self-limiting. Ipamorelin's selective mechanism and natural feedback regulation provide a wide therapeutic index, making serious overdose complications extremely rare at reasonable multiples of therapeutic doses. Always follow recommended dosing guidelines.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Use strict aseptic technique for reconstitution and injection to prevent infection. Rotate injection sites regularly to prevent lipohypertrophy or tissue damage. Monitor blood glucose levels periodically, especially in prediabetic or diabetic individuals. Regular blood tests to monitor IGF-1 levels are recommended during extended use to ensure appropriate dosing. Individuals with carpal tunnel syndrome should use with caution, as GH may exacerbate symptoms. Discontinue use 2 weeks before scheduled surgery due to potential effects on wound healing. Store reconstituted solution refrigerated at 2-8°C and use within 7 days. Avoid concurrent use with other potent GH secretagogues unless under medical supervision. Those with hypertension should monitor blood pressure during initial use.

INTERACTIONS WITH OTHER DRUGS

Potential interactions include: enhanced effects when combined with other GH secretagogues or insulin, possible glucose elevation when used with corticosteroids, potential interference with diabetes medications requiring dosage adjustments, and synergistic actions with anabolic compounds for muscle growth. When combined with insulin or insulin sensitizers, monitor glucose closely. Concurrent use with aromatase inhibitors may require adjustments due to GH's effects on estrogen metabolism. Alcohol may blunt GH response to secretagogues. Beta-blockers may reduce GH response to Ipamorelin. Always disclose all medications and supplements to healthcare providers when using Ipamorelin.

PRESENTATION, PACKAGING

Dragon Pharma Ipamorelin 5 mg is presented in sterile 2 mL glass vials with gray rubber stoppers and blue aluminum seals. Each vial contains 5 mg of lyophilized Ipamorelin powder. Product is available in packs of 5, 10, or 20 vials, often with bacteriostatic water included. Each vial is individually labeled with product name, strength (5 mg/vial), batch number, expiration date, and unique serial number for authenticity verification. Packaging includes tamper-evident features and discreet outer packaging for privacy. Instructions for reconstitution and administration are included with each order. The blue color coding distinguishes it from other Dragon Pharma peptides for easy identification.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in refrigerator. Do not freeze. Protect from light exposure. After reconstitution, store at 2-8°C (36-46°F) and use within 7 days. Do not use if solution appears cloudy, discolored, or contains particulate matter. Avoid temperature fluctuations and repeated freezing/thawing cycles. For travel, use insulated containers with cold packs. Long-term storage (over 6 months) should maintain constant refrigeration. Shelf life of unopened vials is 24 months when stored properly. Keep out of reach of children and pets. Do not use beyond expiration date printed on vial.

DELIVERY TO THE USA

All orders to the United States are shipped discreetly with guaranteed delivery. We utilize multiple shipping carriers with temperature-controlled options available for peptide products. Most orders arrive within 7-10 business days with tracking provided upon shipment. Packaging is plain and unmarked to ensure privacy. We offer reshipment guarantee for orders lost in transit or seized by customs, though seizure rates for research peptides are extremely low. Express shipping options (3-5 business days) available for urgent needs. All packages require signature confirmation for security and verification. Domestic reshipping available for added privacy protection.

LEGAL STATUS

In the United States, Ipamorelin is sold for research purposes only under the provisions of the Dietary Supplement Health and Education Act (DSHEA). It is not FDA-approved for human consumption but is legal to purchase and possess for laboratory research. Not for human consumption, diagnosis, or treatment of any disease. Purchasers assume all responsibility for compliance with local, state, and federal laws. In sports competitions, check specific federation rules as most organizations prohibit growth hormone secretagogues. Always consult with a healthcare professional before beginning any new supplement regimen involving hormonal agents.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - Growth Hormone Secretagogues Mechanisms Review

PROFILE

• Chemical name: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (Ipamorelin acetate)
• Chemical formula: C₄₀H₅₆N₁₂O₆
• Molecular weight: 711.94 g/mol
• Percentage of anabolic activity: Indirect via GH/IGF-1 stimulation
• Percentage of androgenic activity: 0% (not androgenic)
• Active half life: 2-3 hours (subcutaneous administration)
• Recommended dosage: 100-300 mcg daily
• Acne: Possible (via increased IGF-1)
• Bloating (water retention): Possible mild fluid retention
• HBR (Hepatobiliary-related): No hepatotoxicity
• Hepatic toxicity: None reported
• Aromatization: Does not aromatize
• Detection time: 24-48 hours
• Anabolic/Androgenic Ratio: N/A (not anabolic steroid)
• Receptor specificity: Selective GHS-R1a agonist
• Peptide class: Fifth-generation growth hormone secretagogue

Third Party Lab Test

2023-11-20

View Result

5.60 mg